Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
暂无分享,去创建一个
N. Wierup | M. Andersson | M. Cenci | D. Kirik | C. Winkler | M. Lundblad
[1] Erwan Bezard,et al. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.
[2] Y. Agid,et al. Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.
[3] M. Andersson,et al. Alterations in Cortical and Basal Ganglia Levels of Opioid Receptor Binding in a Rat Model of l -DOPA-Induced Dyskinesia , 2001, Neurobiology of Disease.
[4] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[5] W. Poewe,et al. Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[6] A. Björklund,et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. , 2000, Brain : a journal of neurology.
[7] A. Björklund,et al. Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.
[8] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[9] T. Schallert,et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.
[10] A. Lees,et al. Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[11] B. Snow,et al. The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.
[12] P. Bédard,et al. Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[13] M. Andersson,et al. Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.
[14] B. Söderpalm,et al. Naloxone reverses disinhibitory/aggressive behavior in 5,7-DHT-lesioned rats; involvement of GABAA receptor blockade? , 1999, Neuropharmacology.
[15] J. Brotchie,et al. The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease , 1999 .
[16] H. Widner,et al. Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale , 1999, Movement disorders : official journal of the Movement Disorder Society.
[17] L. Grégoire,et al. D1 receptor blockade improves l-dopa–induced dyskinesia but worsens parkinsonism in MPTP monkeys , 1999, Neurology.
[18] J. Qian,et al. Behavioral and Cellular Protection of Rat Dopaminergic Neurons by an Adenoviral Vector Encoding Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.
[19] T. Chase,et al. Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys , 1998, Movement disorders : official journal of the Movement Disorder Society.
[20] A. Björklund,et al. L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.
[21] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[22] J. Brotchie,et al. Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease , 1998, Experimental Neurology.
[23] S. Leff,et al. Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson’s Disease , 1998, The Journal of Neuroscience.
[24] P. Jenner,et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset , 1998, Movement disorders : official journal of the Movement Disorder Society.
[25] S. Leff,et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Labandeira-Garcia,et al. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. , 1997, Brain research. Brain research protocols.
[27] D J Brooks,et al. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.
[28] O. Lindvall. Neural transplantation: a hope for patients with Parkinson's disease , 1997, Neuroreport.
[29] J. Salamone,et al. Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function , 1997, Psychopharmacology.
[30] Y. Agid,et al. Low-dose clozapine improves dyskinesias in Parkinson's disease , 1997, Neurology.
[31] D. Emerich,et al. Validation of a rodent model of Parkinson's disease: Evidence of a therapeutic window for oral Sinemet , 1996, Brain Research Bulletin.
[32] J. P. Huston,et al. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.
[33] E. Chesler,et al. Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements , 1996, Pharmacology Biochemistry and Behavior.
[34] A. Björklund,et al. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.
[35] E. Nestler,et al. Chronic Alterations in Dopaminergic Neurotransmission Produce a Persistent Elevation of ΔFosB‐like Protein(s) in both the Rodent and Primate Striatum , 1996, The European journal of neuroscience.
[36] A. Björklund,et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[37] T. Schallert. Models of neurological defects and defects in neurological models , 1995 .
[38] J. Herman,et al. Dopaminergic neural grafts after fifteen years: results and perspectives , 1994, Progress in Neurobiology.
[39] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[40] P. Bédard,et al. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.
[41] J. Bennett,et al. Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.
[42] P. B. Silverman. Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat. , 1992, European journal of pharmacology.
[43] P. Seeman. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[44] T. Robbins,et al. THE FUNCTIONAL ROLE OF MESOTELENCEPHALIC DOPAMINE SYSTEMS , 1992, Biological reviews of the Cambridge Philosophical Society.
[45] R. Beninger,et al. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine , 1991, Progress in Neurobiology.
[46] R. Carey. Chronicl-DOPA treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance , 1991, Brain Research.
[47] S. Dunnett,et al. The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats , 1991, Journal of Neuroscience Methods.
[48] J. Waddington,et al. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices. , 1990, European journal of pharmacology.
[49] J G Nutt,et al. Levodopa‐induced dyskinesia , 1990, Neurology.
[50] T. Paolo,et al. Chronic treatment withl-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding , 1986, Brain Research.
[51] M. Trabucchi,et al. Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy. , 1982, Archives of neurology.
[52] A. Lees,et al. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. , 1981, Journal of neurology, neurosurgery, and psychiatry.
[53] J. Montastruc,et al. Long-term treatment of Parkinson's disease with bromocriptine. , 1979, Journal of neurology, neurosurgery, and psychiatry.
[54] S. Iversen,et al. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. , 1973, Brain research.
[55] R. M. Fleming,et al. Blockade of the central effects of d-amphetamine sulfate by amantadine hydrochloride. , 1973, European journal of pharmacology.
[56] U. Ungerstedt,et al. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.
[57] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[58] T. Schallert,et al. Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .
[59] J. Montastruc,et al. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients. , 1999, Advances in neurology.
[60] J. Brotchie,et al. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.
[61] J. Brotchie,et al. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. , 1998, Advances in neurology.
[62] R. Carey. Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. , 1991, Life sciences.
[63] E. Silverman,et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. , 1990, Human heredity.
[64] S. Snider,et al. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. , 1986, The American journal of psychiatry.
[65] U. Ungerstedt,et al. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. , 1976, Pharmacology & therapeutics. Part B: General & systematic pharmacology.